ttt_name	others	CAR-T cells	ATC code	concept_class_id	concept_name	concept_code_ancestor_ATC 1st	concept_code_ancestor_ATC 2nd	concept_code_ancestor_ATC 3rd	concept_code_ancestor_ATC 4th	concept_name_ancestor_ATC 1st	concept_name_ancestor_ATC 2nd	concept_name_ancestor_ATC 3rd	concept_name_ancestor_ATC 4th	concept_name_ancestor_ATC 3nd	concept_name_ancestor_ATC 4nd
[177lu]lu-dota-tat	NA	NA	V10XX04	ATC 5th	lutetium (177Lu) oxodotreotide; parenteral	V	V10	V10X	V10XX	VARIOUS	THERAPEUTIC RADIOPHARMACEUTICALS	OTHER THERAPEUTIC RADIOPHARMACEUTICALS	Various therapeutic radiopharmaceuticals	NA	NA
[177lu]lu-dota-tate	NA	NA	V10XX04	ATC 5th	lutetium (177Lu) oxodotreotide; parenteral	V	V10	V10X	V10XX	VARIOUS	THERAPEUTIC RADIOPHARMACEUTICALS	OTHER THERAPEUTIC RADIOPHARMACEUTICALS	Various therapeutic radiopharmaceuticals	NA	NA
/- second stem-cell transplantation (salvage-2)	procedure	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
15-valent pneumococcal conjugate vaccine	NA	NA	J07AL	ATC 4th	Pneumococcal vaccines	J	J07	J07A	J07AL	ANTIINFECTIVES FOR SYSTEMIC USE	VACCINES	BACTERIAL VACCINES	Pneumococcal vaccines	NA	NA
20-valent pneumococcal conjugate vaccine	NA	NA	J07AL	ATC 4th	Pneumococcal vaccines	J	J07	J07A	J07AL	ANTIINFECTIVES FOR SYSTEMIC USE	VACCINES	BACTERIAL VACCINES	Pneumococcal vaccines	NA	NA
abemaciclib	NA	NA	L01EF03	ATC 5th	abemaciclib; oral	L	L01	L01E	L01EF	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Cyclin-dependent kinase (CDK) inhibitors	NA	NA
abiraterone acetate	NA	NA	L02BX03	ATC 5th	abiraterone; oral	L	L02	L02B	L02BX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ENDOCRINE THERAPY	HORMONE ANTAGONISTS AND RELATED AGENTS	Other hormone antagonists and related agents	NA	NA
acalabrutinib	NA	NA	L01EL02	ATC 5th	acalabrutinib; oral	L	L01	L01E	L01EL	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Bruton's tyrosine kinase (BTK) inhibitors	NA	NA
acitretin	NA	NA	D05BB02	ATC 5th	acitretin; oral	D	D05	D05B	D05BB	DERMATOLOGICALS	ANTIPSORIATICS	ANTIPSORIATICS FOR SYSTEMIC USE	Retinoids for treatment of psoriasis	NA	NA
adalimumab	NA	NA	L04AB04	ATC 5th	adalimumab; parenteral	L	L04	L04A	L04AB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Tumor necrosis factor alpha (TNF-a) inhibitors	NA	NA
adalimumab 150mg	NA	NA	L04AB04	ATC 5th	adalimumab; parenteral	L	L04	L04A	L04AB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Tumor necrosis factor alpha (TNF-a) inhibitors	NA	NA
adt	NA	NA	L02BB	ATC 4th	Anti-androgens	L	L02	L02B	L02BB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ENDOCRINE THERAPY	HORMONE ANTAGONISTS AND RELATED AGENTS	Anti-androgens	NA	NA
alectinib	NA	NA	L01ED03	ATC 5th	alectinib; oral	L	L01	L01E	L01ED	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Anaplastic lymphoma kinase (ALK) inhibitors	NA	NA
alemtuzumab	NA	NA	L04AA34	ATC 5th	alemtuzumab; parenteral	L	L04	L04A	L04AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Selective immunosuppressants	NA	NA
amlodipine	NA	NA	C08CA01	ATC 5th	amlodipine; oral	C	C08	C08C	C08CA	CARDIOVASCULAR SYSTEM	CALCIUM CHANNEL BLOCKERS	SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS	Dihydropyridine derivatives	NA	NA
amlodipine 10mg,	NA	NA	C08CA01	ATC 5th	amlodipine; oral	C	C08	C08C	C08CA	CARDIOVASCULAR SYSTEM	CALCIUM CHANNEL BLOCKERS	SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS	Dihydropyridine derivatives	NA	NA
amlodipine 5 mg	NA	NA	C08CA01	ATC 5th	amlodipine; oral	C	C08	C08C	C08CA	CARDIOVASCULAR SYSTEM	CALCIUM CHANNEL BLOCKERS	SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS	Dihydropyridine derivatives	NA	NA
apalutamide	NA	NA	L02BB05	ATC 5th	apalutamide; oral	L	L02	L02B	L02BB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ENDOCRINE THERAPY	HORMONE ANTAGONISTS AND RELATED AGENTS	Anti-androgens	NA	NA
apomorphine sublingual film	NA	NA	G04BE07	ATC 5th	apomorphine; sublingual	G	G04	G04B	G04BE	GENITO URINARY SYSTEM AND SEX HORMONES	UROLOGICALS	UROLOGICALS	Drugs used in erectile dysfunction	NA	NA
apremilast	NA	NA	L04AA32	ATC 5th	apremilast; oral	L	L04	L04A	L04AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Selective immunosuppressants	NA	NA
ard of care	supportive or standard of care	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
asunaprevir	NA	NA	J05AP06	ATC 5th	asunaprevir; systemic	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections	NA	NA
atezolizumab	NA	NA	L01XC32	ATC 5th	atezolizumab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies	NA	NA
atomoxetine	NA	NA	N06BA09	ATC 5th	atomoxetine; oral	N	N06	N06B	N06BA	NERVOUS SYSTEM	PSYCHOANALEPTICS	PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS	Centrally acting sympathomimetics	NA	NA
avapritinib	NA	NA	L01EX18	ATC 5th	L01EX18	L	L01	L01E	L01EX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Other protein kinase inhibitors	NA	NA
axicabtagene ciloleucel	NA	TRUE	L01XX70	ATC 5th	axicabtagene ciloleucel; parenteral	L	L01	L01X	L01XX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Other antineoplastic agents	NA	NA
axitinib	NA	NA	L01EK01	ATC 5th	axitinib; oral	L	L01	L01E	L01EK	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors	NA	NA
azacitidine	NA	NA	L01BC07	ATC 5th	azacitidine; systemic	L	L01	L01B	L01BC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	ANTIMETABOLITES	Pyrimidine analogues	NA	NA
baricitinib	NA	NA	L04AA37	ATC 5th	baricitinib; oral	L	L04	L04A	L04AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Selective immunosuppressants	NA	NA
bax 855	NA	NA	B02BD02	ATC 5th	coagulation factor VIII; parenteral, topical, urethral	B	B02	B02B	B02BD	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Blood coagulation factors	NA	NA
bay 81-8973	NA	NA	B02BD02	ATC 5th	coagulation factor VIII; parenteral, topical, urethral	B	B02	B02B	B02BD	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Blood coagulation factors	NA	NA
bay 81-8973 (recombinant factor viii)	NA	NA	B02BD02	ATC 5th	coagulation factor VIII; parenteral, topical, urethral	B	B02	B02B	B02BD	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Blood coagulation factors	NA	NA
bay 94-9027	NA	NA	B02BD02	ATC 5th	coagulation factor VIII; parenteral, topical, urethral	B	B02	B02B	B02BD	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Blood coagulation factors	NA	NA
belantamab mafodotin	NA	NA	L01XC39	ATC 5th	belantamab mafodotin; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies	NA	NA
bendamustine	NA	NA	L01AA09	ATC 5th	bendamustine; parenteral	L	L01	L01A	L01AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	ALKYLATING AGENTS	Nitrogen mustard analogues	NA	NA
benralizumab	NA	NA	R03DX10	ATC 5th	benralizumab; systemic	R	R03	R03D	R03DX	RESPIRATORY SYSTEM	DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES	OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES	Other systemic drugs for obstructive airway diseases	NA	NA
best supportive care	supportive or standard of care	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
best supportive care (bsc)	supportive or standard of care	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
betamethasone dipropionate aerosol foam	NA	NA	D07XC01	ATC 5th	betamethasone, combinations; topical	D	D07	D07X	D07XC	DERMATOLOGICALS	CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS	CORTICOSTEROIDS, OTHER COMBINATIONS	Corticosteroids, potent, other combinations	NA	NA
bevacizumab	NA	NA	L01XC07	ATC 5th	bevacizumab; ophthalmic, parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies	NA	NA
binimetinib	NA	NA	L01EE03	ATC 5th	binimetinib; oral	L	L01	L01E	L01EE	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Mitogen-activated protein kinase (MEK) inhibitors	NA	NA
bisoprolol	NA	NA	C07AB07	ATC 5th	bisoprolol; oral	C	C07	C07A	C07AB	CARDIOVASCULAR SYSTEM	BETA BLOCKING AGENTS	BETA BLOCKING AGENTS	Beta blocking agents, selective	NA	NA
bisoprolol 5 mg	NA	NA	C07AB07	ATC 5th	bisoprolol; oral	C	C07	C07A	C07AB	CARDIOVASCULAR SYSTEM	BETA BLOCKING AGENTS	BETA BLOCKING AGENTS	Beta blocking agents, selective	NA	NA
blinatumomab	NA	NA	L01XC19	ATC 5th	blinatumomab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies	NA	NA
boceprevir	NA	NA	J05AP03	ATC 5th	boceprevir; oral	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections	NA	NA
bortezomib	NA	NA	L01XG01	ATC 5th	bortezomib; parenteral	L	L01	L01X	L01XG	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Proteasome inhibitors	NA	NA
melphalan	NA	NA	L01AA03	ATC 5th	melphalan; systemic	L	L01	L01A	L01AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	ALKYLATING AGENTS	Nitrogen mustard analogues	NA	NA
prednisone	NA	NA	H02AB07	ATC 5th	prednisone; oral	H	H02	H02A	H02AB	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	CORTICOSTEROIDS FOR SYSTEMIC USE	CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN	Glucocorticoids	NA	NA
bosutinib	NA	NA	L01EA04	ATC 5th	bosutinib; oral	L	L01	L01E	L01EA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Bcr-abl tyrosine kinase inhibitors	NA	NA
brexanolone	NA	NA	N06AX29	NA	NA	N	N06	N06A	N06AX	NERVOUS SYSTEM	PSYCHOANALEPTICS	NA	NA	ANTIDEPRESSANTS	OTHER ANTIDEPRESSANTS
brigatinib	NA	NA	L01ED04	ATC 5th	brigatinib; oral	L	L01	L01E	L01ED	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Anaplastic lymphoma kinase (ALK) inhibitors	NA	NA
brodalumab	NA	NA	L04AC12	ATC 5th	brodalumab; systemic	L	L04	L04A	L04AC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Interleukin inhibitors	NA	NA
cabozantinb	NA	NA	L01EX07	ATC 5th	L01EX07	L	L01	L01E	L01EX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Other protein kinase inhibitors	NA	NA
cabozantinib	NA	NA	L01EX07	ATC 5th	L01EX07	L	L01	L01E	L01EX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Other protein kinase inhibitors	NA	NA
calcipotriene 0.005%	NA	NA	D05AX02	ATC 5th	calcipotriol; topical	D	D05	D05A	D05AX	DERMATOLOGICALS	ANTIPSORIATICS	ANTIPSORIATICS FOR TOPICAL USE	Other antipsoriatics for topical use	NA	NA
calcipotriol	NA	NA	D05AX02	ATC 5th	calcipotriol; topical	D	D05	D05A	D05AX	DERMATOLOGICALS	ANTIPSORIATICS	ANTIPSORIATICS FOR TOPICAL USE	Other antipsoriatics for topical use	NA	NA
carboplatin	NA	NA	L01XA02	ATC 5th	carboplatin; inhalant, parenteral	L	L01	L01X	L01XA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Platinum compounds	NA	NA
carfilzomib	NA	NA	L01XG02	ATC 5th	carfilzomib; parenteral	L	L01	L01X	L01XG	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Proteasome inhibitors	NA	NA
carfizomib	NA	NA	L01XG02	ATC 5th	carfilzomib; parenteral	L	L01	L01X	L01XG	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Proteasome inhibitors	NA	NA
cb catheter (arctic front advancetm)	procedure	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
cemiplimab	NA	NA	L01XC33	ATC 5th	cemiplimab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies	NA	NA
ceritinib	NA	NA	L01ED02	ATC 5th	ceritinib; oral	L	L01	L01E	L01ED	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Anaplastic lymphoma kinase (ALK) inhibitors	NA	NA
certinib	NA	NA	L01ED02	ATC 5th	ceritinib; oral	L	L01	L01E	L01ED	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Anaplastic lymphoma kinase (ALK) inhibitors	NA	NA
cetuximab	NA	NA	L01XC06	ATC 5th	cetuximab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies	NA	NA
chemotherapy	NA	NA	L01	ATC 2nd	ANTINEOPLASTIC AGENTS	L	L01	NA	NA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	NA	NA	NA	NA
chlorambucil	NA	NA	L01AA02	ATC 5th	chlorambucil; oral	L	L01	L01A	L01AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	ALKYLATING AGENTS	Nitrogen mustard analogues	NA	NA
ciltacabtagene autoleucel	NA	TRUE	L01XL05	NA	NA	L	L01	L01X	L01XL	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	NA	NA	OTHER ANTINEOPLASTIC AGENTS	ANTINEOPLASTIC CELL AND GENE THERAPY
cisplatin	NA	NA	L01XA01	ATC 5th	cisplatin; inhalant, parenteral	L	L01	L01X	L01XA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Platinum compounds	NA	NA
cisplatin-based chemotherapy	NA	NA	L01XA01	ATC 5th	cisplatin; inhalant, parenteral	L	L01	L01X	L01XA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Platinum compounds	NA	NA
cladribine	NA	NA	L01BB04	ATC 5th	cladribine; systemic	L	L01	L01B	L01BB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	ANTIMETABOLITES	Purine analogues	NA	NA
cladribine tablets	NA	NA	L01BB04	ATC 5th	cladribine; systemic	L	L01	L01B	L01BB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	ANTIMETABOLITES	Purine analogues	NA	NA
clofarabine	NA	NA	L01BB06	ATC 5th	clofarabine; parenteral	L	L01	L01B	L01BB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	ANTIMETABOLITES	Purine analogues	NA	NA
clofarabine monotherapy	NA	NA	L01BB06	ATC 5th	clofarabine; parenteral	L	L01	L01B	L01BB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	ANTIMETABOLITES	Purine analogues	NA	NA
cobimetinib	NA	NA	L01EE02	ATC 5th	cobimetinib; oral	L	L01	L01E	L01EE	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Mitogen-activated protein kinase (MEK) inhibitors	NA	NA
copanlisib	NA	NA	L01EM02	ATC 5th	copanlisib; oral	L	L01	L01E	L01EM	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Phosphatidylinositol-3-kinase (Pi3K) inhibitors	NA	NA
crisaborole	NA	NA	D11AH06	ATC 5th	crisaborole; topical	D	D11	D11A	D11AH	DERMATOLOGICALS	OTHER DERMATOLOGICAL PREPARATIONS	OTHER DERMATOLOGICAL PREPARATIONS	Agents for dermatitis, excluding corticosteroids	NA	NA
crisaborole ointment 2	NA	NA	D11AH06	ATC 5th	crisaborole; topical	D	D11	D11A	D11AH	DERMATOLOGICALS	OTHER DERMATOLOGICAL PREPARATIONS	OTHER DERMATOLOGICAL PREPARATIONS	Agents for dermatitis, excluding corticosteroids	NA	NA
crisaborole ointment 2%	NA	NA	D11AH06	ATC 5th	crisaborole; topical	D	D11	D11A	D11AH	DERMATOLOGICALS	OTHER DERMATOLOGICAL PREPARATIONS	OTHER DERMATOLOGICAL PREPARATIONS	Agents for dermatitis, excluding corticosteroids	NA	NA
crizotinib	NA	NA	L01ED01	ATC 5th	crizotinib; oral	L	L01	L01E	L01ED	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Anaplastic lymphoma kinase (ALK) inhibitors	NA	NA
cryoballoon (cb) ablation	procedure	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
cyclophosphamide	NA	NA	L01AA01	ATC 5th	cyclophosphamide; systemic	L	L01	L01A	L01AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	ALKYLATING AGENTS	Nitrogen mustard analogues	NA	NA
NA	NA	NA	L01AA03	ATC 5th	melphalan; systemic	L	L01	L01A	L01AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	ALKYLATING AGENTS	Nitrogen mustard analogues	NA	NA
dabrafenib	NA	NA	L01EC02	ATC 5th	dabrafenib; oral	L	L01	L01E	L01EC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	B-raf serine-threonine kinase (BRAF) inhibitors	NA	NA
daclatasvir	NA	NA	J05AP07	ATC 5th	daclatasvir; oral	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections	NA	NA
dacomitinib	NA	NA	L01EB07	ATC 5th	dacomitinib; oral	L	L01	L01E	L01EB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors	NA	NA
damoctocog alfa pegol	NA	NA	B02BD02	ATC 5th	coagulation factor VIII; parenteral, topical, urethral	B	B02	B02B	B02BD	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Blood coagulation factors	NA	NA
damoctocog alfa pegol (bay 94-9027)	NA	NA	B02BD02	ATC 5th	coagulation factor VIII; parenteral, topical, urethral	B	B02	B02B	B02BD	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Blood coagulation factors	NA	NA
damoctocog alfa pegol (pooled prophylaxis)	NA	NA	B02BD02	ATC 5th	coagulation factor VIII; parenteral, topical, urethral	B	B02	B02B	B02BD	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Blood coagulation factors	NA	NA
damoctocog alfa pegol q5d	NA	NA	B02BD02	ATC 5th	coagulation factor VIII; parenteral, topical, urethral	B	B02	B02B	B02BD	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Blood coagulation factors	NA	NA
damoctocog alfa pegol q7d	NA	NA	B02BD02	ATC 5th	coagulation factor VIII; parenteral, topical, urethral	B	B02	B02B	B02BD	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Blood coagulation factors	NA	NA
damoctocog alfa pegol twice weekly	NA	NA	B02BD02	ATC 5th	coagulation factor VIII; parenteral, topical, urethral	B	B02	B02B	B02BD	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Blood coagulation factors	NA	NA
daratumumab	NA	NA	L01XC24	ATC 5th	daratumumab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies	NA	NA
darolutamide	NA	NA	L02BB06	ATC 5th	darolutamide; oral	L	L02	L02B	L02BB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ENDOCRINE THERAPY	HORMONE ANTAGONISTS AND RELATED AGENTS	Anti-androgens	NA	NA
dasatinib	NA	NA	L01EA02	ATC 5th	dasatinib; oral	L	L01	L01E	L01EA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Bcr-abl tyrosine kinase inhibitors	NA	NA
dbragenib	NA	NA	L01EC02	ATC 5th	dabrafenib; oral	L	L01	L01E	L01EC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	B-raf serine-threonine kinase (BRAF) inhibitors	NA	NA
decitabine	NA	NA	L01BC08	ATC 5th	decitabine; systemic	L	L01	L01B	L01BC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	ANTIMETABOLITES	Pyrimidine analogues	NA	NA
delayed- release dimethyl fumarate	NA	NA	L04AX07	ATC 5th	dimethyl fumarate; oral	L	L04	L04A	L04AX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Other immunosuppressants	NA	NA
delayed-release dimethyl fumarate	NA	NA	L04AX07	ATC 5th	dimethyl fumarate; oral	L	L04	L04A	L04AX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Other immunosuppressants	NA	NA
deutetrabenazine	NA	NA	N07XX16	ATC 5th	deutetrabenazine; oral	N	N07	N07X	N07XX	NERVOUS SYSTEM	OTHER NERVOUS SYSTEM DRUGS	OTHER NERVOUS SYSTEM DRUGS	Other nervous system drugs	NA	NA
dexamethasone	NA	NA	H02AB02	ATC 5th	dexamethasone; systemic	H	H02	H02A	H02AB	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	CORTICOSTEROIDS FOR SYSTEMIC USE	CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN	Glucocorticoids	NA	NA
dimethyl fumarate	NA	NA	L04AX07	ATC 5th	dimethyl fumarate; oral	L	L04	L04A	L04AX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Other immunosuppressants	NA	NA
dimethyl fumarate 240 mg twice daily	NA	NA	L04AX07	ATC 5th	dimethyl fumarate; oral	L	L04	L04A	L04AX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Other immunosuppressants	NA	NA
dulaglutide	NA	NA	A10BJ05	ATC 5th	dulaglutide; parenteral	A	A10	A10B	A10BJ	ALIMENTARY TRACT AND METABOLISM	DRUGS USED IN DIABETES	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS	Glucagon-like peptide-1 (GLP-1) analogues	NA	NA
dulaglutide 1.5 mg	NA	NA	A10BJ05	ATC 5th	dulaglutide; parenteral	A	A10	A10B	A10BJ	ALIMENTARY TRACT AND METABOLISM	DRUGS USED IN DIABETES	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS	Glucagon-like peptide-1 (GLP-1) analogues	NA	NA
dulaglutide 3.0	NA	NA	A10BJ05	ATC 5th	dulaglutide; parenteral	A	A10	A10B	A10BJ	ALIMENTARY TRACT AND METABOLISM	DRUGS USED IN DIABETES	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS	Glucagon-like peptide-1 (GLP-1) analogues	NA	NA
dulaglutide 3.0 mg	NA	NA	A10BJ05	ATC 5th	dulaglutide; parenteral	A	A10	A10B	A10BJ	ALIMENTARY TRACT AND METABOLISM	DRUGS USED IN DIABETES	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS	Glucagon-like peptide-1 (GLP-1) analogues	NA	NA
dulaglutide 3.0mg	NA	NA	A10BJ05	ATC 5th	dulaglutide; parenteral	A	A10	A10B	A10BJ	ALIMENTARY TRACT AND METABOLISM	DRUGS USED IN DIABETES	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS	Glucagon-like peptide-1 (GLP-1) analogues	NA	NA
dulaglutide 4.5 mg	NA	NA	A10BJ05	ATC 5th	dulaglutide; parenteral	A	A10	A10B	A10BJ	ALIMENTARY TRACT AND METABOLISM	DRUGS USED IN DIABETES	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS	Glucagon-like peptide-1 (GLP-1) analogues	NA	NA
dulaglutide 4.5mg	NA	NA	A10BJ05	ATC 5th	dulaglutide; parenteral	A	A10	A10B	A10BJ	ALIMENTARY TRACT AND METABOLISM	DRUGS USED IN DIABETES	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS	Glucagon-like peptide-1 (GLP-1) analogues	NA	NA
dupilumab	NA	NA	D11AH05	ATC 5th	dupilumab; topical	D	D11	D11A	D11AH	DERMATOLOGICALS	OTHER DERMATOLOGICAL PREPARATIONS	OTHER DERMATOLOGICAL PREPARATIONS	Agents for dermatitis, excluding corticosteroids	NA	NA
duvelisib	NA	NA	L01EM04	ATC 5th	duvelisib; oral	L	L01	L01E	L01EM	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Phosphatidylinositol-3-kinase (Pi3K) inhibitors	NA	NA
emicizumab every 2 weeks	NA	NA	B02BX06	ATC 5th	emicizumab; parenteral	B	B02	B02B	B02BX	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Other systemic hemostatics	NA	NA
emicizumab every 4 weeks	NA	NA	B02BX06	ATC 5th	emicizumab; parenteral	B	B02	B02B	B02BX	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Other systemic hemostatics	NA	NA
emicizumab every week	NA	NA	B02BX06	ATC 5th	emicizumab; parenteral	B	B02	B02B	B02BX	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Other systemic hemostatics	NA	NA
emicizumab q1w	NA	NA	B02BX06	ATC 5th	emicizumab; parenteral	B	B02	B02B	B02BX	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Other systemic hemostatics	NA	NA
emicizumab q2w regimen	NA	NA	B02BX06	ATC 5th	emicizumab; parenteral	B	B02	B02B	B02BX	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Other systemic hemostatics	NA	NA
emicizumab q4w regimen	NA	NA	B02BX06	ATC 5th	emicizumab; parenteral	B	B02	B02B	B02BX	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Other systemic hemostatics	NA	NA
encorafenib	NA	NA	L01EC03	ATC 5th	encorafenib; oral	L	L01	L01E	L01EC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	B-raf serine-threonine kinase (BRAF) inhibitors	NA	NA
entrectinib	NA	NA	L01EX14	ATC 5th	L01EX14	L	L01	L01E	L01EX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Other protein kinase inhibitors	NA	NA
enzalutamide	NA	NA	L02BB04	ATC 5th	enzalutamide; oral	L	L02	L02B	L02BB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ENDOCRINE THERAPY	HORMONE ANTAGONISTS AND RELATED AGENTS	Anti-androgens	NA	NA
erenumab	NA	NA	N02CD01	ATC 5th	erenumab; parenteral	N	N02	N02C	N02CD	NERVOUS SYSTEM	ANALGESICS	ANTIMIGRAINE PREPARATIONS	Calcitonin gene-related peptide (CGRP) antagonists	NA	NA
erlotinib	NA	NA	L01EB02	ATC 5th	erlotinib; oral (epidermal growth factor receptor (egfr) tyrosine kinase inhibitors)	L	L01	L01E	L01EB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors	NA	NA
etanercept	NA	NA	L04AB01	ATC 5th	etanercept; parenteral	L	L04	L04A	L04AB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Tumor necrosis factor alpha (TNF-a) inhibitors	NA	NA
etoposide	NA	NA	L01CB01	ATC 5th	etoposide; systemic	L	L01	L01C	L01CB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS	Podophyllotoxin derivatives	NA	NA
everolimus	NA	NA	L01EG02	ATC 5th	everolimus; oral (mammalian target of rapamycin kinase inhibitors (mtor))	L	L01	L01E	L01EG	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Mammalian target of rapamycin (mTOR) kinase inhibitors	NA	NA
fingolimod	NA	NA	L04AA27	ATC 5th	fingolimod; oral	L	L04	L04A	L04AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Selective immunosuppressants	NA	NA
fingolimod 0.5mg	NA	NA	L04AA27	ATC 5th	fingolimod; oral	L	L04	L04A	L04AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Selective immunosuppressants	NA	NA
folfirinox	NA	NA	L01	ATC 2nd	ANTINEOPLASTIC AGENTS	L	L01	NA	NA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	NA	NA	NA	NA
fulvestran	NA	NA	L02BA03	ATC 5th	fulvestrant; parenteral	L	L02	L02B	L02BA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ENDOCRINE THERAPY	HORMONE ANTAGONISTS AND RELATED AGENTS	Anti-estrogens	NA	NA
fulvestrant	NA	NA	L02BA03	ATC 5th	fulvestrant; parenteral	L	L02	L02B	L02BA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ENDOCRINE THERAPY	HORMONE ANTAGONISTS AND RELATED AGENTS	Anti-estrogens	NA	NA
fumaric acid esters	NA	NA	D05BX51	ATC 5th	fumaric acid derivatives, combinations; systemic	D	D05	D05B	D05BX	DERMATOLOGICALS	ANTIPSORIATICS	ANTIPSORIATICS FOR SYSTEMIC USE	Other antipsoriatics for systemic use	NA	NA
NA	NA	NA	D05AX01	ATC 5th	fumaric acid; topical	D	D05	D05A	D05AX	DERMATOLOGICALS	ANTIPSORIATICS	ANTIPSORIATICS FOR TOPICAL USE	Other antipsoriatics for topical use	NA	NA
fviiifc	NA	NA	B02BD02	ATC 5th	coagulation factor VIII; parenteral, topical, urethral	B	B02	B02B	B02BD	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Blood coagulation factors	NA	NA
galcanezumab	NA	NA	N02CD02	ATC 5th	galcanezumab; parenteral	N	N02	N02C	N02CD	NERVOUS SYSTEM	ANALGESICS	ANTIMIGRAINE PREPARATIONS	Calcitonin gene-related peptide (CGRP) antagonists	NA	NA
gefitinib	NA	NA	L01EB01	ATC 5th	gefitinib; oral (epidermal growth factor receptor (egfr) tyrosine kinase inhibitors)	L	L01	L01E	L01EB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors	NA	NA
gemcitabine	NA	NA	L01BC05	ATC 5th	gemcitabine; parenteral	L	L01	L01B	L01BC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	ANTIMETABOLITES	Pyrimidine analogues	NA	NA
glasdegib	NA	NA	L01XJ03	ATC 5th	glasdegib; oral	L	L01	L01X	L01XJ	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Hedgehog pathway inhibitors	NA	NA
glatiramer acetate	NA	NA	L03AX13	ATC 5th	glatiramer acetate; parenteral	L	L03	L03A	L03AX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSTIMULANTS	IMMUNOSTIMULANTS	Other immunostimulants	NA	NA
guanfacine extended release	NA	NA	C02AC02	ATC 5th	guanfacine; oral	C	C02	C02A	C02AC	CARDIOVASCULAR SYSTEM	ANTIHYPERTENSIVES	ANTIADRENERGIC AGENTS, CENTRALLY ACTING	Imidazoline receptor agonists	NA	NA
guanfacine extended-release high dose	NA	NA	C02AC02	ATC 5th	guanfacine; oral	C	C02	C02A	C02AC	CARDIOVASCULAR SYSTEM	ANTIHYPERTENSIVES	ANTIADRENERGIC AGENTS, CENTRALLY ACTING	Imidazoline receptor agonists	NA	NA
guanfacine extended-release low dose	NA	NA	C02AC02	ATC 5th	guanfacine; oral	C	C02	C02A	C02AC	CARDIOVASCULAR SYSTEM	ANTIHYPERTENSIVES	ANTIADRENERGIC AGENTS, CENTRALLY ACTING	Imidazoline receptor agonists	NA	NA
guanfacine extended-release mid dose	NA	NA	C02AC02	ATC 5th	guanfacine; oral	C	C02	C02A	C02AC	CARDIOVASCULAR SYSTEM	ANTIHYPERTENSIVES	ANTIADRENERGIC AGENTS, CENTRALLY ACTING	Imidazoline receptor agonists	NA	NA
guselkuma	NA	NA	L04AC16	ATC 5th	guselkumab; systemic	L	L04	L04A	L04AC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Interleukin inhibitors	NA	NA
guselkumab	NA	NA	L04AC16	ATC 5th	guselkumab; systemic	L	L04	L04A	L04AC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Interleukin inhibitors	NA	NA
halobetasol	NA	NA	D07AC21	ATC 5th	ulobetasol; topical	D	D07	D07A	D07AC	DERMATOLOGICALS	CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS	CORTICOSTEROIDS, PLAIN	Corticosteroids, potent (group III)	NA	NA
tazarotene	NA	NA	D05AX05	ATC 5th	tazarotene; topical	D	D05	D05A	D05AX	DERMATOLOGICALS	ANTIPSORIATICS	ANTIPSORIATICS FOR TOPICAL USE	Other antipsoriatics for topical use	NA	NA
ibrutinib	NA	NA	L01EL01	ATC 5th	ibrutinib; oral	L	L01	L01E	L01EL	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Bruton's tyrosine kinase (BTK) inhibitors	NA	NA
ibrutinib1	NA	NA	L01EL01	ATC 5th	ibrutinib; oral	L	L01	L01E	L01EL	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Bruton's tyrosine kinase (BTK) inhibitors	NA	NA
idecabtagene	NA	TRUE	L01XL07	NA	NA	L	L01	L01X	L01XL	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	NA	NA	OTHER ANTINEOPLASTIC AGENTS	ANTINEOPLASTIC CELL AND GENE THERAPY
idecabtagene vicleucel	NA	TRUE	L01XL07	NA	NA	L	L01	L01X	L01XL	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	NA	NA	OTHER ANTINEOPLASTIC AGENTS	ANTINEOPLASTIC CELL AND GENE THERAPY
idelalisib	NA	NA	L01EM01	ATC 5th	idelalisib; oral	L	L01	L01E	L01EM	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Phosphatidylinositol-3-kinase (Pi3K) inhibitors	NA	NA
ifnβ-1a 22 μg once weekly (qw)	NA	NA	L03AB07	ATC 5th	interferon beta-1a; parenteral	L	L03	L03A	L03AB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSTIMULANTS	IMMUNOSTIMULANTS	Interferons	NA	NA
ifnβ-1b 250 μg once every other day (q2d)	NA	NA	L03AB08	ATC 5th	interferon beta-1b; parenteral	L	L03	L03A	L03AB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSTIMULANTS	IMMUNOSTIMULANTS	Interferons	NA	NA
ifnβ-1b 8 miu once every other day	NA	NA	L03AB08	ATC 5th	interferon beta-1b; parenteral	L	L03	L03A	L03AB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSTIMULANTS	IMMUNOSTIMULANTS	Interferons	NA	NA
im ifnβ-1a 60 μg once weekly	NA	NA	L03AB07	ATC 5th	interferon beta-1a; parenteral	L	L03	L03A	L03AB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSTIMULANTS	IMMUNOSTIMULANTS	Interferons	NA	NA
infliximab	NA	NA	L04AB02	ATC 5th	infliximab; parenteral	L	L04	L04A	L04AB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Tumor necrosis factor alpha (TNF-a) inhibitors	NA	NA
inotersen	NA	NA	N07XX15	ATC 5th	inotersen; parenteral	N	N07	N07X	N07XX	NERVOUS SYSTEM	OTHER NERVOUS SYSTEM DRUGS	OTHER NERVOUS SYSTEM DRUGS	Other nervous system drugs	NA	NA
inotuzumab ozogamicin	NA	NA	L01XC26	ATC 5th	inotuzumab ozogamicin; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies	NA	NA
intravenous methylprednisolone	NA	NA	H02AB04	ATC 5th	methylprednisolone; systemic	H	H02	H02A	H02AB	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	CORTICOSTEROIDS FOR SYSTEMIC USE	CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN	Glucocorticoids	NA	NA
intravitreally administered aflibercept (ivt-afl) : one injection every 8 weeks in the first year followed by prorenata regimen in the second year,	NA	NA	S01LA05	ATC 5th	aflibercept; ophthalmic	S	S01	S01L	S01LA	SENSORY ORGANS	OPHTHALMOLOGICALS	OCULAR VASCULAR DISORDER AGENTS	Antineovascularisation agents	NA	NA
intravitreally administered aflibercept (ivt-afl) with 2 weeks adjustment	NA	NA	S01LA05	ATC 5th	aflibercept; ophthalmic	S	S01	S01L	S01LA	SENSORY ORGANS	OPHTHALMOLOGICALS	OCULAR VASCULAR DISORDER AGENTS	Antineovascularisation agents	NA	NA
intravitreally administered aflibercept 8 weeks	NA	NA	S01LA05	ATC 5th	aflibercept; ophthalmic	S	S01	S01L	S01LA	SENSORY ORGANS	OPHTHALMOLOGICALS	OCULAR VASCULAR DISORDER AGENTS	Antineovascularisation agents	NA	NA
intravitreally administered aflibercept treat-	NA	NA	S01LA05	ATC 5th	aflibercept; ophthalmic	S	S01	S01L	S01LA	SENSORY ORGANS	OPHTHALMOLOGICALS	OCULAR VASCULAR DISORDER AGENTS	Antineovascularisation agents	NA	NA
ipilimumab	NA	NA	L01XC11	ATC 5th	ipilimumab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies	NA	NA
ixekizumab	NA	NA	L04AC13	ATC 5th	ixekizumab; parenteral	L	L04	L04A	L04AC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Interleukin inhibitors	NA	NA
ledipasvir	NA	NA	J05AP51	ATC 5th	sofosbuvir and ledipasvir; systemic	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections	NA	NA
lenalidomide	NA	NA	L04AX04	ATC 5th	lenalidomide; oral	L	L04	L04A	L04AX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Other immunosuppressants	NA	NA
lenalidomide-dexamethasone	NA	NA	L04AX04	ATC 5th	lenalidomide; oral	L	L04	L04A	L04AX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Other immunosuppressants	NA	NA
lenalidomide-dexamethasone	NA	NA	H02AB02	ATC 5th	dexamethasone; systemic	H	H02	H02A	H02AB	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	CORTICOSTEROIDS FOR SYSTEMIC USE	CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN	Glucocorticoids	NA	NA
lenalidomide-dexamethasone 18 months (rd18)	NA	NA	L04AX04	ATC 5th	lenalidomide; oral	L	L04	L04A	L04AX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Other immunosuppressants	NA	NA
lenalidomide-dexamethasone 18 months (rd18)	NA	NA	H02AB02	ATC 5th	dexamethasone; systemic	H	H02	H02A	H02AB	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	CORTICOSTEROIDS FOR SYSTEMIC USE	CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN	Glucocorticoids	NA	NA
lenalidomide-dexamethasone continuou	NA	NA	L04AX04	ATC 5th	lenalidomide; oral	L	L04	L04A	L04AX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Other immunosuppressants	NA	NA
lenalidomide-dexamethasone continuou	NA	NA	H02AB02	ATC 5th	dexamethasone; systemic	H	H02	H02A	H02AB	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	CORTICOSTEROIDS FOR SYSTEMIC USE	CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN	Glucocorticoids	NA	NA
lenvatinib	NA	NA	L01EX08	ATC 5th	L01EX08	L	L01	L01E	L01EX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Other protein kinase inhibitors	NA	NA
letrozole	NA	NA	L02BG04	ATC 5th	letrozole; oral	L	L02	L02B	L02BG	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ENDOCRINE THERAPY	HORMONE ANTAGONISTS AND RELATED AGENTS	Aromatase inhibitors	NA	NA
levodopa inhalation powder	NA	NA	N04BA01	ATC 5th	levodopa; oral	N	N04	N04B	N04BA	NERVOUS SYSTEM	ANTI-PARKINSON DRUGS	DOPAMINERGIC AGENTS	Dopa and dopa derivatives	NA	NA
liso-cel	NA	TRUE	L01XL	NA	NA	L	L01	L01X	L01XL	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	NA	NA	OTHER ANTINEOPLASTIC AGENTS	ANTINEOPLASTIC CELL AND GENE THERAPY
lisocabtagene	NA	TRUE	L01XL	NA	NA	L	L01	L01X	L01XL	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	NA	NA	OTHER ANTINEOPLASTIC AGENTS	ANTINEOPLASTIC CELL AND GENE THERAPY
lisocabtagene maraleucel	NA	TRUE	L01XL	NA	NA	L	L01	L01X	L01XL	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	NA	NA	OTHER ANTINEOPLASTIC AGENTS	ANTINEOPLASTIC CELL AND GENE THERAPY
lorlatinib	NA	NA	L01ED05	ATC 5th	lorlatinib; oral	L	L01	L01E	L01ED	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Anaplastic lymphoma kinase (ALK) inhibitors	NA	NA
low-dos ecytarabine	NA	NA	L01BC01	ATC 5th	cytarabine; systemic	L	L01	L01B	L01BC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	ANTIMETABOLITES	Pyrimidine analogues	NA	NA
low-dose cytarabine	NA	NA	L01BC01	ATC 5th	cytarabine; systemic	L	L01	L01B	L01BC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	ANTIMETABOLITES	Pyrimidine analogues	NA	NA
low-dose cytarabine.	NA	NA	L01BC01	ATC 5th	cytarabine; systemic	L	L01	L01B	L01BC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	ANTIMETABOLITES	Pyrimidine analogues	NA	NA
low-dose dexamethasone	NA	NA	H02AB02	ATC 5th	dexamethasone; systemic	H	H02	H02A	H02AB	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	CORTICOSTEROIDS FOR SYSTEMIC USE	CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN	Glucocorticoids	NA	NA
magnetic resonance-guided focused ultrasound	procedure	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
melphalan-prednisone-thalidomide	NA	NA	L01AA03	ATC 5th	melphalan; systemic	L	L01	L01A	L01AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	ALKYLATING AGENTS	Nitrogen mustard analogues	NA	NA
melphalan-prednisone-thalidomide	NA	NA	L04AX02	ATC 5th	thalidomide; oral	L	L04	L04A	L04AX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Other immunosuppressants	NA	NA
melphalan-prednisone-thalidomide	NA	NA	H02AB07	ATC 5th	prednisone; oral	H	H02	H02A	H02AB	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	CORTICOSTEROIDS FOR SYSTEMIC USE	CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN	Glucocorticoids	NA	NA
melphalan-prednisone-thalidomide (mpt)	NA	NA	L01AA03	ATC 5th	melphalan; systemic	L	L01	L01A	L01AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	ALKYLATING AGENTS	Nitrogen mustard analogues	NA	NA
melphalan-prednisone-thalidomide (mpt)	NA	NA	L04AX02	ATC 5th	thalidomide; oral	L	L04	L04A	L04AX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Other immunosuppressants	NA	NA
melphalan-prednisone-thalidomide (mpt)	NA	NA	H02AB07	ATC 5th	prednisone; oral	H	H02	H02A	H02AB	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	CORTICOSTEROIDS FOR SYSTEMIC USE	CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN	Glucocorticoids	NA	NA
mepolizumab	NA	NA	R03DX09	ATC 5th	mepolizumab; parenteral	R	R03	R03D	R03DX	RESPIRATORY SYSTEM	DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES	OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES	Other systemic drugs for obstructive airway diseases	NA	NA
methotrexate	NA	NA	L01BA01	ATC 5th	methotrexate; systemic (folic acid analog.)	L	L01	L01B	L01BA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	ANTIMETABOLITES	Folic acid analogues	NA	NA
methotrexate	NA	NA	L01AA03	ATC 5th	melphalan; systemic	L	L01	L01A	L01AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	ALKYLATING AGENTS	Nitrogen mustard analogues	NA	NA
midostaurin	NA	NA	L01EX10	ATC 5th	L01EX10	L	L01	L01E	L01EX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Other protein kinase inhibitors	NA	NA
midostaurin	NA	NA	L01AA03	ATC 5th	melphalan; systemic	L	L01	L01A	L01AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	ALKYLATING AGENTS	Nitrogen mustard analogues	NA	NA
modified bortezomib-melphalan-prednisone schedules	NA	NA	L01AA03	ATC 5th	melphalan; systemic	L	L01	L01A	L01AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	ALKYLATING AGENTS	Nitrogen mustard analogues	NA	NA
modified bortezomib-melphalan-prednisone schedules	NA	NA	L01XG01	ATC 5th	bortezomib; parenteral	L	L01	L01X	L01XG	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Proteasome inhibitors	NA	NA
modified bortezomib-melphalan-prednisone schedules	NA	NA	H02AB07	ATC 5th	prednisone; oral	H	H02	H02A	H02AB	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	CORTICOSTEROIDS FOR SYSTEMIC USE	CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN	Glucocorticoids	NA	NA
modified vmp (bortezomib/melphalan/prednisone) schedule	NA	NA	L01AA03	ATC 5th	melphalan; systemic	L	L01	L01A	L01AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	ALKYLATING AGENTS	Nitrogen mustard analogues	NA	NA
modified vmp (bortezomib/melphalan/prednisone) schedule	NA	NA	L01XG01	ATC 5th	bortezomib; parenteral	L	L01	L01X	L01XG	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Proteasome inhibitors	NA	NA
modified vmp (bortezomib/melphalan/prednisone) schedule	NA	NA	H02AB07	ATC 5th	prednisone; oral	H	H02	H02A	H02AB	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	CORTICOSTEROIDS FOR SYSTEMIC USE	CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN	Glucocorticoids	NA	NA
nab-paclitaxel	NA	NA	L01CD01	ATC 5th	paclitaxel; systemic	L	L01	L01C	L01CD	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS	Taxanes	NA	NA
natalizumab	NA	NA	L04AA23	ATC 5th	natalizumab; parenteral	L	L04	L04A	L04AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Selective immunosuppressants	NA	NA
nilotinib	NA	NA	L01EA03	ATC 5th	nilotinib; oral	L	L01	L01E	L01EA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Bcr-abl tyrosine kinase inhibitors	NA	NA
niraparib	NA	NA	L01XK02	ATC 5th	niraparib; oral	L	L01	L01X	L01XK	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Poly (ADP-ribose) polymerase (PARP) inhibitors	NA	NA
nivolumab	NA	NA	L01XC17	ATC 5th	nivolumab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies	NA	NA
nusinersen	NA	NA	M09AX07	ATC 5th	nusinersen; systemic	M	M09	M09A	M09AX	MUSCULO-SKELETAL SYSTEM	OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM	OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM	Other drugs for disorders of the musculo-skeletal system	NA	NA
obinutuzumab	NA	NA	L01XC15	ATC 5th	obinutuzumab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies	NA	NA
sofosbuvir/ ledipasvir	NA	NA	J05AP51	ATC 5th	sofosbuvir and ledipasvir; systemic	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections	NA	NA
olaparib	NA	NA	L01XK01	ATC 5th	olaparib; oral	L	L01	L01X	L01XK	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Poly (ADP-ribose) polymerase (PARP) inhibitors	NA	NA
onasemnogene abeparvovec	NA	NA	M09AX09	ATC 5th	onasemnogene abeparvovec; parenteral	M	M09	M09A	M09AX	MUSCULO-SKELETAL SYSTEM	OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM	OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM	Other drugs for disorders of the musculo-skeletal system	NA	NA
onasemnogeneabeparvovec	NA	NA	M09AX09	ATC 5th	onasemnogene abeparvovec; parenteral	M	M09	M09A	M09AX	MUSCULO-SKELETAL SYSTEM	OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM	OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM	Other drugs for disorders of the musculo-skeletal system	NA	NA
ozanimod	NA	NA	L04AA38	ATC 5th	ozanimod; oral	L	L04	L04A	L04AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Selective immunosuppressants	NA	NA
padua downstaging protocol	NA	NA	L01	ATC 2nd	ANTINEOPLASTIC AGENTS	L	L01	NA	NA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	NA	NA	NA	NA
padua surgical aggressive downstaging	NA	NA	L01	ATC 2nd	ANTINEOPLASTIC AGENTS	L	L01	NA	NA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	NA	NA	NA	NA
palbociclib	NA	NA	L01EF01	ATC 5th	palbociclib; oral	L	L01	L01E	L01EF	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Cyclin-dependent kinase (CDK) inhibitors	NA	NA
paliative therapy/salvage therapy	NA	NA	L01	ATC 2nd	ANTINEOPLASTIC AGENTS	L	L01	NA	NA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	NA	NA	NA	NA
palliative therapy/salvage therapy	NA	NA	L01	ATC 2nd	ANTINEOPLASTIC AGENTS	L	L01	NA	NA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	NA	NA	NA	NA
panitumumab	NA	NA	L01XC08	ATC 5th	panitumumab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies	NA	NA
panobinostat	NA	NA	L01XH03	ATC 5th	panobinostat; oral	L	L01	L01X	L01XH	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Histone deacetylase (HDAC) inhibitors	NA	NA
patisiran	NA	NA	N07XX12	ATC 5th	patisiran; parenteral	N	N07	N07X	N07XX	NERVOUS SYSTEM	OTHER NERVOUS SYSTEM DRUGS	OTHER NERVOUS SYSTEM DRUGS	Other nervous system drugs	NA	NA
pcv20 (prevnar 20, a 20-valent pneumococcal conjugate vaccine)	NA	NA	J07AL	ATC 4th	Pneumococcal vaccines	J	J07	J07A	J07AL	ANTIINFECTIVES FOR SYSTEMIC USE	VACCINES	BACTERIAL VACCINES	Pneumococcal vaccines	NA	NA
pegcetacoplan	NA	NA	L04AA54	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
peginterferon alfa- 2a	NA	NA	L03AB11	ATC 5th	peginterferon alfa-2a; parenteral	L	L03	L03A	L03AB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSTIMULANTS	IMMUNOSTIMULANTS	Interferons	NA	NA
peginterferon alfa-2a	NA	NA	L03AB11	ATC 5th	peginterferon alfa-2a; parenteral	L	L03	L03A	L03AB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSTIMULANTS	IMMUNOSTIMULANTS	Interferons	NA	NA
peginterferon alpha 2a	NA	NA	L03AB11	ATC 5th	peginterferon alfa-2a; parenteral	L	L03	L03A	L03AB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSTIMULANTS	IMMUNOSTIMULANTS	Interferons	NA	NA
peginterferon beta-1a	NA	NA	L03AB13	ATC 5th	peginterferon beta-1a; parenteral	L	L03	L03A	L03AB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSTIMULANTS	IMMUNOSTIMULANTS	Interferons	NA	NA
peginterferon-alfa	NA	NA	L03AB11	ATC 5th	peginterferon alfa-2a; parenteral	L	L03	L03A	L03AB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSTIMULANTS	IMMUNOSTIMULANTS	Interferons	NA	NA
peginterferon-alfa	NA	NA	L03AB12	ATC 5th	albinterferon alfa-2b; systemic	L	L03	L03A	L03AB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSTIMULANTS	IMMUNOSTIMULANTS	Interferons	NA	NA
peginterferon-α	NA	NA	L03AB11	ATC 5th	peginterferon alfa-2a; parenteral	L	L03	L03A	L03AB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSTIMULANTS	IMMUNOSTIMULANTS	Interferons	NA	NA
peginterferon-α	NA	NA	L03AB12	ATC 5th	albinterferon alfa-2b; systemic	L	L03	L03A	L03AB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSTIMULANTS	IMMUNOSTIMULANTS	Interferons	NA	NA
pembrolizumab	NA	NA	L01XC18	ATC 5th	pembrolizumab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies	NA	NA
pemetrexed	NA	NA	L01BA04	ATC 5th	pemetrexed; inhalant, parenteral	L	L01	L01B	L01BA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	ANTIMETABOLITES	Folic acid analogues	NA	NA
pemetrexed maintenance	NA	NA	L01BA04	ATC 5th	pemetrexed; inhalant, parenteral	L	L01	L01B	L01BA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	ANTIMETABOLITES	Folic acid analogues	NA	NA
pemetrexed or docetaxel	NA	NA	L01BA04	ATC 5th	pemetrexed; inhalant, parenteral	L	L01	L01B	L01BA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	ANTIMETABOLITES	Folic acid analogues	NA	NA
pemetrexed or docetaxel	NA	NA	L01CD02	ATC 5th	docetaxel; parenteral	L	L01	L01C	L01CD	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS	Taxanes	NA	NA
pemetrexed/docetaxel	NA	NA	L01BA04	ATC 5th	pemetrexed; inhalant, parenteral	L	L01	L01B	L01BA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	ANTIMETABOLITES	Folic acid analogues	NA	NA
pemetrexed/docetaxel	NA	NA	L01CD02	ATC 5th	docetaxel; parenteral	L	L01	L01C	L01CD	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS	Taxanes	NA	NA
docetaxel	NA	NA	L01CD02	ATC 5th	docetaxel; parenteral	L	L01	L01C	L01CD	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS	Taxanes	NA	NA
pimecrolimus 1%	NA	NA	D11AH02	ATC 5th	pimecrolimus; topical	D	D11	D11A	D11AH	DERMATOLOGICALS	OTHER DERMATOLOGICAL PREPARATIONS	OTHER DERMATOLOGICAL PREPARATIONS	Agents for dermatitis, excluding corticosteroids	NA	NA
placebo	placebo	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
platinum	NA	NA	L01XA	ATC 4th	Platinum compounds	L	L01	L01X	L01XA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Platinum compounds	NA	NA
platinum followed by pemetrexed maintenance	NA	NA	L01XA	ATC 4th	Platinum compounds	L	L01	L01X	L01XA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Platinum compounds	NA	NA
platinum followed by pemetrexed maintenance	NA	NA	L01BA04	ATC 5th	pemetrexed; inhalant, parenteral	L	L01	L01B	L01BA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	ANTIMETABOLITES	Folic acid analogues	NA	NA
permetrexed maintenance	NA	NA	L01BA04	ATC 5th	pemetrexed; inhalant, parenteral	L	L01	L01B	L01BA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	ANTIMETABOLITES	Folic acid analogues	NA	NA
platinum-based chemotherapy	NA	NA	L01XA	ATC 4th	Platinum compounds	L	L01	L01X	L01XA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Platinum compounds	NA	NA
polychemotherapy/high-dose single-agent regimens/stem-cell transplantation (salvage-1)	NA	NA	L01XA	ATC 4th	Platinum compounds	L	L01	L01X	L01XA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Platinum compounds	NA	NA
pomalidomide	NA	NA	L04AX06	ATC 5th	pomalidomide; oral	L	L04	L04A	L04AX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Other immunosuppressants	NA	NA
ponatinib	NA	NA	L01EA05	ATC 5th	ponatinib; oral	L	L01	L01E	L01EA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Bcr-abl tyrosine kinase inhibitors	NA	NA
prior episodic treatment rfixfc	NA	NA	B02BD04	ATC 5th	coagulation factor IX; parenteral	B	B02	B02B	B02BD	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Blood coagulation factors	NA	NA
prior episodic treatment rix-fp	NA	NA	B02BD04	ATC 5th	coagulation factor IX; parenteral	B	B02	B02B	B02BD	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Blood coagulation factors	NA	NA
prior prophylaxis rfixfc	NA	NA	B02BD04	ATC 5th	coagulation factor IX; parenteral	B	B02	B02B	B02BD	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Blood coagulation factors	NA	NA
prior prophylaxis rix-fp	NA	NA	B02BD04	ATC 5th	coagulation factor IX; parenteral	B	B02	B02B	B02BD	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Blood coagulation factors	NA	NA
radiofrequency (rf) ablation with ablation index	procedure	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
rahf-pfm	NA	NA	B02BD02	ATC 5th	coagulation factor VIII; parenteral, topical, urethral	B	B02	B02B	B02BD	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Blood coagulation factors	NA	NA
rahf-pfm (2004 study)	NA	NA	B02BD02	ATC 5th	coagulation factor VIII; parenteral, topical, urethral	B	B02	B02B	B02BD	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Blood coagulation factors	NA	NA
rahf-pfm (2012 study)	NA	NA	B02BD02	ATC 5th	coagulation factor VIII; parenteral, topical, urethral	B	B02	B02B	B02BD	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Blood coagulation factors	NA	NA
rahf-pfm 2004	NA	NA	B02BD02	ATC 5th	coagulation factor VIII; parenteral, topical, urethral	B	B02	B02B	B02BD	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Blood coagulation factors	NA	NA
rahf-pfm 2012	NA	NA	B02BD02	ATC 5th	coagulation factor VIII; parenteral, topical, urethral	B	B02	B02B	B02BD	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Blood coagulation factors	NA	NA
rahf-pfm octocog alf	NA	NA	B02BD02	ATC 5th	coagulation factor VIII; parenteral, topical, urethral	B	B02	B02B	B02BD	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Blood coagulation factors	NA	NA
rahf-pfm octocog alfa	NA	NA	B02BD02	ATC 5th	coagulation factor VIII; parenteral, topical, urethral	B	B02	B02B	B02BD	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Blood coagulation factors	NA	NA
ramucirumab	NA	NA	L01XC21	ATC 5th	ramucirumab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies	NA	NA
ratiofrequency catheter ablation with ablation index	procedure	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
ratiofrequency catheter ablation with cryoballoon	procedure	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
ravulizumab	NA	NA	L04AA43	ATC 5th	ravulizumab; parenteral	L	L04	L04A	L04AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Selective immunosuppressants	NA	NA
recombinant fviiifc	NA	NA	B02BD02	ATC 5th	coagulation factor VIII; parenteral, topical, urethral	B	B02	B02B	B02BD	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Blood coagulation factors	NA	NA
regorafenib	NA	NA	L01EX05	ATC 5th	L01EX05	L	L01	L01E	L01EX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Other protein kinase inhibitors	NA	NA
remestemcel-l-rknd	NA	NA	L04A	ATC 3rd	IMMUNOSUPPRESSANTS	L	L04	L04A	NA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	NA	NA	NA
rfixfc (regimen prior to study entry : prior prophylaxis)	NA	NA	B02BD04	ATC 5th	coagulation factor IX; parenteral	B	B02	B02B	B02BD	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Blood coagulation factors	NA	NA
rfixfc (treatment regimen prior to study entry : prior on-dem	NA	NA	B02BD04	ATC 5th	coagulation factor IX; parenteral	B	B02	B02B	B02BD	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Blood coagulation factors	NA	NA
rfviiifc	NA	NA	B02BD02	ATC 5th	coagulation factor VIII; parenteral, topical, urethral	B	B02	B02B	B02BD	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Blood coagulation factors	NA	NA
rfviiifc (efmoroctocog alfa)	NA	NA	B02BD02	ATC 5th	coagulation factor VIII; parenteral, topical, urethral	B	B02	B02B	B02BD	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Blood coagulation factors	NA	NA
ribavirin	NA	NA	J05AP01	ATC 5th	ribavirin; inhalant, oral	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections	NA	NA
ribavirine	NA	NA	J05AP01	ATC 5th	ribavirin; inhalant, oral	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections	NA	NA
ribociclib	NA	NA	L01EF02	ATC 5th	ribociclib; oral	L	L01	L01E	L01EF	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Cyclin-dependent kinase (CDK) inhibitors	NA	NA
rimegepant	NA	NA	N02CD06	ATC 5th	rimegepant; oral	N	N02	N02C	N02CD	NERVOUS SYSTEM	ANALGESICS	ANTIMIGRAINE PREPARATIONS	Calcitonin gene-related peptide (CGRP) antagonists	NA	NA
risankizumab	NA	NA	L04AC18	ATC 5th	risankizumab; parenteral	L	L04	L04A	L04AC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Interleukin inhibitors	NA	NA
risdiplam	NA	NA	M09AX10	ATC 5th	risdiplam; oral	M	M09	M09A	M09AX	MUSCULO-SKELETAL SYSTEM	OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM	OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM	Other drugs for disorders of the musculo-skeletal system	NA	NA
rituximab	NA	NA	L01XC02	ATC 5th	rituximab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies	NA	NA
rivaroxaban	NA	NA	B01AF01	ATC 5th	rivaroxaban; oral	B	B01	B01A	B01AF	BLOOD AND BLOOD FORMING ORGANS	ANTITHROMBOTIC AGENTS	ANTITHROMBOTIC AGENTS	Direct factor Xa inhibitors	NA	NA
rix-fp	NA	NA	B02BD04	ATC 5th	coagulation factor IX; parenteral	B	B02	B02B	B02BD	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Blood coagulation factors	NA	NA
routine clinical practice	supportive or standard of care	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
routine clinical practice (rcp)	supportive or standard of care	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
ruxolitinib	NA	NA	L01EJ01	ATC 5th	ruxolitinib; oral	L	L01	L01E	L01EJ	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Janus-associated kinase (JAK) inhibitors	NA	NA
rviii-singlechain	NA	NA	B02BD02	ATC 5th	coagulation factor VIII; parenteral, topical, urethral	B	B02	B02B	B02BD	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Blood coagulation factors	NA	NA
rviii-singlechain lonoctocog alfa	NA	NA	B02BD02	ATC 5th	coagulation factor VIII; parenteral, topical, urethral	B	B02	B02B	B02BD	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Blood coagulation factors	NA	NA
salvage chemotherapy	NA	NA	L01	ATC 2nd	ANTINEOPLASTIC AGENTS	L	L01	NA	NA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	NA	NA	NA	NA
salvage chemotherapy/treatment	NA	NA	L01	ATC 2nd	ANTINEOPLASTIC AGENTS	L	L01	NA	NA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	NA	NA	NA	NA
sc ifnβ-1a 22 μg three times weekly	NA	NA	L03AB07	ATC 5th	interferon beta-1a; parenteral	L	L03	L03A	L03AB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSTIMULANTS	IMMUNOSTIMULANTS	Interferons	NA	NA
sc ifnβ-1a 44 μg three times weekly	NA	NA	L03AB07	ATC 5th	interferon beta-1a; parenteral	L	L03	L03A	L03AB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSTIMULANTS	IMMUNOSTIMULANTS	Interferons	NA	NA
second-generation cryoballoon (cb)	procedure	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
secukinumab	NA	NA	L04AC10	ATC 5th	secukinumab; parenteral	L	L04	L04A	L04AC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Interleukin inhibitors	NA	NA
secukinumab 150 mg	NA	NA	L04AC10	ATC 5th	secukinumab; parenteral	L	L04	L04A	L04AC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Interleukin inhibitors	NA	NA
secukinumab 150mg	NA	NA	L04AC10	ATC 5th	secukinumab; parenteral	L	L04	L04A	L04AC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Interleukin inhibitors	NA	NA
secukinumab 300 mg	NA	NA	L04AC10	ATC 5th	secukinumab; parenteral	L	L04	L04A	L04AC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Interleukin inhibitors	NA	NA
secukinumab 300mg	NA	NA	L04AC10	ATC 5th	secukinumab; parenteral	L	L04	L04A	L04AC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Interleukin inhibitors	NA	NA
selinexor	NA	NA	L01XX66	ATC 5th	selinexor; oral	L	L01	L01X	L01XX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Other antineoplastic agents	NA	NA
semaglutide	NA	NA	A10BJ06	ATC 5th	semaglutide; parenteral	A	A10	A10B	A10BJ	ALIMENTARY TRACT AND METABOLISM	DRUGS USED IN DIABETES	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS	Glucagon-like peptide-1 (GLP-1) analogues	NA	NA
semaglutide 0.5	NA	NA	A10BJ06	ATC 5th	semaglutide; parenteral	A	A10	A10B	A10BJ	ALIMENTARY TRACT AND METABOLISM	DRUGS USED IN DIABETES	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS	Glucagon-like peptide-1 (GLP-1) analogues	NA	NA
semaglutide 1.0 mg	NA	NA	A10BJ06	ATC 5th	semaglutide; parenteral	A	A10	A10B	A10BJ	ALIMENTARY TRACT AND METABOLISM	DRUGS USED IN DIABETES	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS	Glucagon-like peptide-1 (GLP-1) analogues	NA	NA
semaglutide 1.0mg	NA	NA	A10BJ06	ATC 5th	semaglutide; parenteral	A	A10	A10B	A10BJ	ALIMENTARY TRACT AND METABOLISM	DRUGS USED IN DIABETES	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS	Glucagon-like peptide-1 (GLP-1) analogues	NA	NA
semaglutide 2.0 m	NA	NA	A10BJ06	ATC 5th	semaglutide; parenteral	A	A10	A10B	A10BJ	ALIMENTARY TRACT AND METABOLISM	DRUGS USED IN DIABETES	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS	Glucagon-like peptide-1 (GLP-1) analogues	NA	NA
semaglutide 2.0 mg	NA	NA	A10BJ06	ATC 5th	semaglutide; parenteral	A	A10	A10B	A10BJ	ALIMENTARY TRACT AND METABOLISM	DRUGS USED IN DIABETES	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS	Glucagon-like peptide-1 (GLP-1) analogues	NA	NA
semaglutide 2.0mg	NA	NA	A10BJ06	ATC 5th	semaglutide; parenteral	A	A10	A10B	A10BJ	ALIMENTARY TRACT AND METABOLISM	DRUGS USED IN DIABETES	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS	Glucagon-like peptide-1 (GLP-1) analogues	NA	NA
simeprevir	NA	NA	J05AP05	ATC 5th	simeprevir; oral	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections	NA	NA
siponimod	NA	NA	L04AA42	ATC 5th	siponimod; oral	L	L04	L04A	L04AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Selective immunosuppressants	NA	NA
sitagliptin 100 mg	NA	NA	A10BH01	ATC 5th	sitagliptin; oral	A	A10	A10B	A10BH	ALIMENTARY TRACT AND METABOLISM	DRUGS USED IN DIABETES	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS	Dipeptidyl peptidase 4 (DPP-4) inhibitors	NA	NA
sitagliptin 100 mg once daily	NA	NA	A10BH01	ATC 5th	sitagliptin; oral	A	A10	A10B	A10BH	ALIMENTARY TRACT AND METABOLISM	DRUGS USED IN DIABETES	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS	Dipeptidyl peptidase 4 (DPP-4) inhibitors	NA	NA
sitagliptin 50 mg	NA	NA	A10BH01	ATC 5th	sitagliptin; oral	A	A10	A10B	A10BH	ALIMENTARY TRACT AND METABOLISM	DRUGS USED IN DIABETES	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS	Dipeptidyl peptidase 4 (DPP-4) inhibitors	NA	NA
sitagliptin 50 mg once daily	NA	NA	A10BH01	ATC 5th	sitagliptin; oral	A	A10	A10B	A10BH	ALIMENTARY TRACT AND METABOLISM	DRUGS USED IN DIABETES	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS	Dipeptidyl peptidase 4 (DPP-4) inhibitors	NA	NA
sofosbuvir	NA	NA	J05AP08	ATC 5th	sofosbuvir; oral	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections	NA	NA
sonidegib	NA	NA	L01XJ02	ATC 5th	sonidegib; oral	L	L01	L01X	L01XJ	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Hedgehog pathway inhibitors	NA	NA
sunitinb	NA	NA	L01EX01	ATC 5th	L01EX01	L	L01	L01E	L01EX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Other protein kinase inhibitors	NA	NA
sunitinib	NA	NA	L01EX01	ATC 5th	L01EX01	L	L01	L01E	L01EX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Other protein kinase inhibitors	NA	NA
systemic therapy	supportive or standard of care	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
tacrolimus 0.03%	NA	NA	D11AH01	ATC 5th	tacrolimus; topical	D	D11	D11A	D11AH	DERMATOLOGICALS	OTHER DERMATOLOGICAL PREPARATIONS	OTHER DERMATOLOGICAL PREPARATIONS	Agents for dermatitis, excluding corticosteroids	NA	NA
tacrolimus 0.1%	NA	NA	D11AH01	ATC 5th	tacrolimus; topical	D	D11	D11A	D11AH	DERMATOLOGICALS	OTHER DERMATOLOGICAL PREPARATIONS	OTHER DERMATOLOGICAL PREPARATIONS	Agents for dermatitis, excluding corticosteroids	NA	NA
tare using sir-spheres (radioembolization)	procedure	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
tazemetostat	NA	NA	L01XX72	ATC 5th	tazemetostat; oral	L	L01	L01X	L01XX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Other antineoplastic agents	NA	NA
telaprevir	NA	NA	J05AP02	ATC 5th	telaprevir; oral	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections	NA	NA
temsirolimus	NA	NA	L01EG01	ATC 5th	temsirolimus; parenteral	L	L01	L01E	L01EG	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Mammalian target of rapamycin (mTOR) kinase inhibitors	NA	NA
teprotumumab	NA	NA	L04AA53	ATC 5th	teprotumumab; parenteral	L	L04	L04A	L04AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Selective immunosuppressants	NA	NA
teriflunomide	NA	NA	L04AA31	ATC 5th	teriflunomide; oral	L	L04	L04A	L04AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Selective immunosuppressants	NA	NA
teriflunomide 14 mg	NA	NA	L04AA31	ATC 5th	teriflunomide; oral	L	L04	L04A	L04AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Selective immunosuppressants	NA	NA
teriflunomide 14mg	NA	NA	L04AA31	ATC 5th	teriflunomide; oral	L	L04	L04A	L04AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Selective immunosuppressants	NA	NA
teriflunomide 7 mg	NA	NA	L04AA31	ATC 5th	teriflunomide; oral	L	L04	L04A	L04AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Selective immunosuppressants	NA	NA
teriflunomide 7mg	NA	NA	L04AA31	ATC 5th	teriflunomide; oral	L	L04	L04A	L04AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Selective immunosuppressants	NA	NA
tetrabenazine	NA	NA	N07XX06	ATC 5th	tetrabenazine; oral	N	N07	N07X	N07XX	NERVOUS SYSTEM	OTHER NERVOUS SYSTEM DRUGS	OTHER NERVOUS SYSTEM DRUGS	Other nervous system drugs	NA	NA
thalidomide	NA	NA	L04AX02	ATC 5th	thalidomide; oral	L	L04	L04A	L04AX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Other immunosuppressants	NA	NA
thermocool smarttouchtm catheter or the thermocool smarttouchtm sf catheter with ai/visitag surpointtm module	procedure	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
thermocool smarttouch™/thermocool smarttouch™ sf catheter with ai (stai)	procedure	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
tildrakizumab 100mg	NA	NA	L04AC17	ATC 5th	tildrakizumab; parenteral	L	L04	L04A	L04AC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Interleukin inhibitors	NA	NA
tildrakizumab 200mg	NA	NA	L04AC17	ATC 5th	tildrakizumab; parenteral	L	L04	L04A	L04AC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Interleukin inhibitors	NA	NA
tisagenlecleucel	NA	NA	L01XX71	ATC 5th	tisagenlecleucel; parenteral	L	L01	L01X	L01XX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Other antineoplastic agents	NA	NA
tocilizumab	NA	NA	L04AC07	ATC 5th	tocilizumab; parenteral	L	L04	L04A	L04AC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Interleukin inhibitors	NA	NA
tofacitinib	NA	NA	L04AA29	ATC 5th	tofacitinib; oral	L	L04	L04A	L04AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Selective immunosuppressants	NA	NA
total disc replacemen	procedure	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
total disc replacement (tdr)	procedure	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
trametinib	NA	NA	L01EE01	ATC 5th	trametinib; oral	L	L01	L01E	L01EE	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Mitogen-activated protein kinase (MEK) inhibitors	NA	NA
transarterial radioembolization using sir-spheres(R) y-90 resin microspheres	procedure	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
turoctocog alfa	NA	NA	B02BD02	ATC 5th	coagulation factor VIII; parenteral, topical, urethral	B	B02	B02B	B02BD	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Blood coagulation factors	NA	NA
turoctocog alfa pegol	NA	NA	B02BD02	ATC 5th	coagulation factor VIII; parenteral, topical, urethral	B	B02	B02B	B02BD	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Blood coagulation factors	NA	NA
turoctocog alfa pegol (n8-gp)	NA	NA	B02BD02	ATC 5th	coagulation factor VIII; parenteral, topical, urethral	B	B02	B02B	B02BD	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Blood coagulation factors	NA	NA
umbralisib	NA	NA	L01EX25	ATC 5th	umbralisib: oral	L	L01	L01E	L01EX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Other protein kinase inhibitors	NA	NA
unilateral deep brain stimulation	procedure	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
unilateral deep brain stimulation (dbs)	procedure	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
upadacitinib	NA	NA	L04AA44	ATC 5th	upadacitinib; oral	L	L04	L04A	L04AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Selective immunosuppressants	NA	NA
upadacitinib monotherapy	NA	NA	L04AA44	ATC 5th	upadacitinib; oral	L	L04	L04A	L04AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Selective immunosuppressants	NA	NA
v114 (vaxneuvance, a 15-valent pneumococcal conjugate vaccine)	NA	NA	J07AL	ATC 4th	Pneumococcal vaccines	J	J07	J07A	J07AL	ANTIINFECTIVES FOR SYSTEMIC USE	VACCINES	BACTERIAL VACCINES	Pneumococcal vaccines	NA	NA
velcade	NA	NA	L01XG01	ATC 5th	bortezomib; parenteral	L	L01	L01X	L01XG	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Proteasome inhibitors	NA	NA
vemurafenib	NA	NA	L01EC01	ATC 5th	vemurafenib; oral	L	L01	L01E	L01EC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	B-raf serine-threonine kinase (BRAF) inhibitors	NA	NA
venetoclax	NA	NA	L01XX52	ATC 5th	venetoclax; oral	L	L01	L01X	L01XX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Other antineoplastic agents	NA	NA
vicleucel	NA	TRUE	L01XL07	NA	NA	L	L01	L01X	L01XL	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	NA	NA	OTHER ANTINEOPLASTIC AGENTS	ANTINEOPLASTIC CELL AND GENE THERAPY
vildagliptin	NA	NA	A10BH02	ATC 5th	vildagliptin; oral	A	A10	A10B	A10BH	ALIMENTARY TRACT AND METABOLISM	DRUGS USED IN DIABETES	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS	Dipeptidyl peptidase 4 (DPP-4) inhibitors	NA	NA
vildagliptin 50 mg twice daily	NA	NA	A10BH02	ATC 5th	vildagliptin; oral	A	A10	A10B	A10BH	ALIMENTARY TRACT AND METABOLISM	DRUGS USED IN DIABETES	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS	Dipeptidyl peptidase 4 (DPP-4) inhibitors	NA	NA
vismodegib	NA	NA	L01XJ01	ATC 5th	vismodegib; oral	L	L01	L01X	L01XJ	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Hedgehog pathway inhibitors	NA	NA
vmp (bortezomib/melphalan/prednisone)	NA	NA	L01AA03	ATC 5th	melphalan; systemic	L	L01	L01A	L01AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	ALKYLATING AGENTS	Nitrogen mustard analogues	NA	NA
vmp (bortezomib/melphalan/prednisone)	NA	NA	L01XG01	ATC 5th	bortezomib; parenteral	L	L01	L01X	L01XG	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Proteasome inhibitors	NA	NA
vmp (bortezomib/melphalan/prednisone)	NA	NA	H02AB07	ATC 5th	prednisone; oral	H	H02	H02A	H02AB	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	CORTICOSTEROIDS FOR SYSTEMIC USE	CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN	Glucocorticoids	NA	NA
xxl protocol downstaging	NA	NA	L01	ATC 2nd	ANTINEOPLASTIC AGENTS	L	L01	NA	NA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	NA	NA	NA	NA
xxl trial downstaging protocol	NA	NA	L01	ATC 2nd	ANTINEOPLASTIC AGENTS	L	L01	NA	NA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	NA	NA	NA	NA
